• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Rev Med Pharmacol Sci . Diagnostic role of laboratory findings and clinical symptoms in detecting the severity of COVID-19 disease

tetano

Editor, Senior Moderator
Eur Rev Med Pharmacol Sci


. 2023 Jun;27(12):5909-5917.
doi: 10.26355/eurrev_202306_32830. Diagnostic role of laboratory findings and clinical symptoms in detecting the severity of COVID-19 disease

M Alshipli[SUP] 1 [/SUP], T A Altaim, O Khodrog, M Hawamdeh, S A Alsenany, S M F Abdelaliem, M Marashdeh, T Hammudeh, T Alnawafleh, R A M Gaowgzeh



Affiliations
Abstract

Objective: The novel coronavirus (COVID-19) pandemic poses a monumental challenge to healthcare systems worldwide. Clinical features and data-driven decisions could differentiate the virus's early stages. This study aims to provide valuable diagnostic data that can help determine the severity of COVID-19 infection and allow for early detection.
Patients and methods: A sample of 214 patients was collected to validate our approach. The data were grouped into ordinary (126 cases) or severe (88 cases) groups. The information they provided included age, gender, creatinine levels, blood pressure, glucose levels, creatine phosphokinase (CPK), alanine transaminase (ALT), cough, fever, expectoration, myalgia, headache, dyspnea, abdominal discomfort, and chest pain. Statistically, the Mann-Whitney U, T, and Chi-square tests were utilized to determine the significant differences in collected data between two groups of patients and the severity of those differences between categorical variables.
Results: The patients' age range was 21 to 84 years. The male gender was predominant (56%), particularly in the severe group (63.6%). The results summarized that the mortality rate for COVID-19 patients is high (4.7%). Symptomatic patients with abnormal creatinine levels, blood pressure, glucose level, CPK, ALT, cough, expectoration, dyspnea, and chest pain were significantly linked with both COVID-19 patient groups (p < 0.05). Compared to the ordinary group, patients in the severe group had abnormal creatinine levels (77.8%), high blood pressure (87.5%), diabetes mellitus (55.3%), high CPK level (85.7%), high ALT value (88.2%), cough (44.4%), expectoration (86.7%), dyspnea (81.0%), and chest pain (80.0%).
Conclusions: Patients with abnormal creatinine levels, blood pressure, glucose levels, CPK, ALT, cough, dyspnea, and chest pain are at high risk for severe COVID-19 infection.


 
Back
Top Bottom